Methotrexate-induced Acute Myelopathy in a Teenager With High-risk Acute Lymphoblastic Leukemia. Issue 4 (May 2020)

• Record Type: Journal Article
• Authors: Geurten, Claire; Forget, Patricia; Leroy, Patricia; Barrea, Christophe; Hoyoux, Claire
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 4(2020)
• Publication Date: 2020-05
• Subjects: acute lymphoblastic leukemia -- myelitis -- methotrexate -- neurotoxicity -- intrathecal therapy; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001374
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Acute lymphoblastic leukemia (ALL) is one of the most frequent malignancies in childhood whose long-term survival has increased up to 80% thanks to modern therapy enhancements. Nevertheless, methotrexate (MTX) remains a mainstay of ALL therapy, but also represents one of the major causes of neurotoxicity in patients with ALL. MTX-induced toxicity occurs in about 9% of patients treated for ALL. It usually affects deep white matter region leading to leukoencephalopathy, which has varying clinical manifestations ranging from acute neurologic disturbances to seizures or chronic permanent encephalopathy. Here we describe a 13-year-old girl affected with ALL who developed lower limbs hypesthesia and static ataxia due to transverse myelopathy after intrathec administration of MTX therapy. A high-dose corticotherapy combined to vitamin supplementation and rehabilitation was tested. Neurological evolution was characterized by slow and partial recovery.